Chronic Fatigue Syndrome Presents Challenging Test Case For PDUFA V Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The first of 20 patient-focused drug development meetings kicks off April 25 with a workshop on CFS and myalgic encephalomyelitis; FDA can expect to hear extensive patient testimony about an array of symptoms and co-morbid conditions, as well as some dissension within the patient community over how the two conditions should be viewed.